SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported) January
25, 2006
CHEMBIO
DIAGNOSTIC, INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
0-30379
|
88-0425691
|
||
|
(State
or other jurisdiction
|
(Commission
File Number)
|
(IRS
Employer
|
||
|
of
Incorporation)
|
Identification
Number)
|
|||
|
3661
Horseblock Road
|
||||
|
Medford,
NY 11763
|
||||
|
(Address
of principal executive offices)
|
||||
|
631-924-1135
|
||||
|
(Registrant’s
Telephone Number)
|
N/A
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM
7.01. Regulation FD Disclosures.
(a) On
January 25, 2006 the Registrant issued the press release titled “Chembio
Appoints Distributor for its Rapid HIV Tests in Tanzania” included herein as
Exhibit 99.1.
ITEM
9.01. Financial Statements and Exhibits
(c) Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
Date:
January 25, 2006 Chembio
Diagnostics, Inc.
By:
/s/
Lawrence A. Siebert
Lawrence
A. Siebert
Chief
Executive Officer
Exhibit
99.1 - Press Release
Chembio
Appoints Distributor for its Rapid HIV Tests in Tanzania
Regional
Director Establishing Regional Distribution Network to Serve Expected
Demand
MEDFORD,
N.Y. - January 25, 2006 - Chembio Diagnostics, Inc. (OTCBB:CEMI) has appointed
Anudha, Ltd. to distribute the company’s rapid HIV tests in Tanzania. Anudha
Ltd. is a well known distributor in Tanzania that works closely with the
Tanzanian government.
Chembio,
whose HIV STAT-PAK(TM) Dipstick is part of the national testing protocol
in
Uganda, established a regional office in Tanzania in June 2005 led by Dr.
Jay
Drosin. The Company believes there will be a significant scale-up in the
demand
for rapid HIV tests in Tanzania and other countries in the region which have
been ravaged by AIDS. Tanzania is one of fifty countries worldwide that is
part
of the Clinton HIV/AIDS Initiative Procurement Consortium. Chembio was recently
selected by the Clinton HIV/AIDS Initiative (“CHAI”) as one of four global
suppliers to these countries pursuant to Memoranda of Understanding (MOU)
CHAI
has with them. For further information please see www.clintonfoundation.org.
African
countries are the largest recipients of international funds for treating
AIDS
through programs that include the current U.S. President’s $15 billion Emergency
Plan for AIDS Relief, as well as other multi-lateral programs affiliated
with
the United Nations such as the UNAIDS ‘3 by 5’ initiative. Combating HIV/AIDS
can only be achieved by a massive scale-up of rapid testing.
Chembio’s
Tanzanian distributor, Anudha Ltd, distributes a full range of hospital and
laboratory equipment, diagnostics and reagents along with surgical accessories
and consumables. Anudha Ltd. is also a consultant to the Tanzanian Ministry
of
Health.
ABOUT
CHEMBIO
Chembio
Diagnostics, Inc. (Chembio) possesses expertise in the development and
manufacturing of rapid test products for various infectious diseases, including
HIV, Tuberculosis
and
Chagas Disease. References to Chembio Diagnostics, Inc. may actually refer
to
Chembio Diagnostic Systems, Inc.; the 100%-owned subsidiary of Chembio
Diagnostics, Inc. Chembio is located at 3661 Horseblock Road, Medford, NY
11763.
For additional information please visit www.chembio.com.
FORWARD-LOOKING
STATEMENTS
Statements
contained herein that are not historical facts may be forward-looking statements
within the meaning of the Securities Act of 1933, as amended. Forward-looking
statements include statements regarding the intent, belief or current
expectations of the Company and its management Such statements are estimates
only, as the Company has not completed the preparation of its financial
statements for those periods, nor has its auditor completed the audit of
those
results. Actual revenue may differ materially from those anticipated in this
press release. Such statements reflect management's current views, are based
on
certain assumptions and involve risks and uncertainties. Actual results,
events,
or performance may differ materially from the above forward-looking statements
due to a number of important factors, and will be dependent upon a variety
of
factors, including, but not limited to Chembio's ability to obtain additional
financing, to obtain regulatory approvals in a timely manner, and the demand
for
Chembio's products. Chembio undertakes no obligation to publicly update these
forward-looking statements to reflect events or circumstances that occur
after
the date hereof or to reflect any change in Chembio's expectations with regard
to these forward-looking statements or the occurrence of unanticipated events.
Factors that may impact Chembio's success are more fully disclosed in Chembio's
most recent public filings with the U.S. Securities and Exchange
Commission.
Contact:
Vince
Daniels/James Carbonara
The
Investor Relations Group 212-825-3210